Promising Phase II Data For Sanofi’s Hemlibra Rival Fitusiran
Gene Therapy Also Approaching Market
Sanofi has unveiled encouraging Phase II data for fitusiran, a novel RNA-based hemophilia therapy which could eventually challenge Roche’s blockbuster Hemlibra.
You may also be interested in...
Sanofi's R&D operation has shaken the dust of diabetes off its feet with an update on its ambitious pipeline plans at an R&D day event.
Latest results show a show decline in effects, but still offers freedom from injections with almost no bleeds recorded in 13 patients.
A composite endpoint conceals Actemra’s lack of mortality benefit – while life-saving dexamethasone gets EMA endorsement.